News
APR 28, 2021
Neuraly Announces Publication in Acta Neuropathologica Communications of Preclinical Data Detailing the Neuroprotective Effect of NLY01 in Models of Alzheimer’s Disease
NLY01 selectively blocks β-amyloid-induced activation of microglia through upregulated GLP-1R. Neuronal viability was preserved, resulting in improved spatial learning and memory
MAR 5, 2021
Qi Cui, AGS 2021: The GLP-1R Agonist NLY01 Reduces Neuroinflammation and Protects against RGC Loss in a Preclinical Glaucoma Model
We were delighted to catch up with Dr Qi Cui (Scheie Eye Institute, University of Pennsylvania, PA, USA), who told us about her research on the GLP-1R agonist NLY01 and the next steps for clinical development.
NOV 10, 2020
Neuraly Announces Research Agreement with the University of Pennsylvania to Explore Use of NLY01 for Glaucoma
Study recently published by Penn team in Cell Reports provides evidence that NLY01 has the potential for clinical use in the treatment of glaucoma and potentially other retinal diseases
NOV 2, 2020
Receiving FDA Clearance of IND Application to Initiate Phase 2B Trial of NLY01 for Patients with AD
Neuraly announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimer’s disease.
MAR 3, 2020
Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease
Neuraly announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease.
NOV 5, 2019
The Neuraly Trial
This week a new clinical trial was registered which caught our attention here at the SoPD HQ. It is being sponsored by a small biotech called Neuraly and involves a drug called NLY01.
OCT 4, 2019
Monster investment puts Baltimore on biotech startup map
With neuroinflammation, fibrosis, genomics and apoptosis research to the fore, Johns Hopkins is ramping up its output of startups with a little help from Korea.
AUG 14, 2019
D&D Pharmatech raises $137.1M in series B financing to advance potential disease-modifying treatments
The financing was led by U.S.-based Octave Life Sciences and included major Korean venture funds Smilegate Investment as co-lead, along with InterVest, Magna Investment and LB Investment, all Series A investors.
JUL 18, 2018
Startup Neuraly raises $36M to bring potential disease-modifying treatments to patients with Parkinson’s disease
Today, Neuraly announced its launch to pioneer the development of disease-modifying agents for neurodegenerative disorders.
JUN 28, 2018
Diabetes drug affects neurodegeneration, PD via immunity
Scientists at the Johns Hopkins Medical School have demonstrated that the experimental glucagon-like peptide 1 (GLP-1) receptor agonist NLY-01 (Neuraly Inc.) was protective against Parkinson's disease (PD) in two separate mouse models.
OCT 30, 2017
Neuraly and South Korea-based 1st Biotherapeutics agreed to co-develop brain penetrant c-Abl inhibitors for Parkinson’s disease
Neuraly Inc., a startup from Johns Hopkins School of Medicine and South Korea-based 1st Biotherapeutics Inc. agreed to co-develop brain penetrant c-Abl inhibitors for Parkinson's disease with aims to file an investigational new drug (IND) application with the FDA next year.
JUN 13, 2018
Does taming killer astrocytes spare neurons in Parkinson’s disease?
Activated microglia contribute to neurodegenerative diseases, and recent work suggests they do that, at least in part, by riling up normally protective astrocytes to attack and kill neurons.